In the Phase 2 LOTIS-2 clinical trial, researchers evaluated the safety, efficacy, and tolerability of Loncastuximab tesirine for patients with aggressive diffuse large B-cell lymphoma (DLBCL). While there are treatment…
How does disease stage affect treatments and patient outcomes? In terms of adrenocortical carcinoma (ACC) in pediatric patients, disease stage significantly impacts patient outcomes. According to Cancer Therapy Advisor, the…
782 words (source) vs. 472 words (mine) - 1% match Some rare diseases or rare cancers are exceedingly difficult to treat. For example, for patients with early-stage cutaneous T-cell lymphoma…
A recent study conducted by researchers at the Broad Institute of MIT and Harvard University uncovered that a small group of cancer cells is responsible for recurrence. Considering that most…
According to Pharmaceutical Business Review, Abecma (idecabtagene vicleucel), a CAR T-cell therapy designed to treat patients with relapsed and refractory (R/R) multiple myeloma (MM), received conditional marketing authorization from the…
Clinical trials are often used to understand the safety, efficacy, and tolerability of specific treatments. Unfortunately, sometimes the drugs in these studies fail. According to Targeted Oncology, this occurred in…
Chimeric antigen receptor (CAR) T-cell therapy has proven to be a successful therapy for a number of conditions; however, we do not see the same success in follicular lymphoma and…
Recent data published in Gynecologic Oncology has confirmed the safety of olaparib for the treatment of advanced, BRCA-mutated, newly diagnosed ovarian cancer. This data came from the Phase 3 SOLO1 trial,…
Ashley Monroe is an extremely talented singer-songwriter who hails from Tennessee. Over the years, Ashley has grown her music career alone and as part of the Pistol Annies. But now…
Nearly all cases of Wilms tumors, a rare form of pediatric kidney cancer, are diagnosed before a child turns 10 years old. When Maddie Newburn was first diagnosed, she was…
Drug development is important in creating new therapeutic options for patients with rare or chronic illnesses. One incentivizing program is the Orphan Drug program. Orphan Drug designation is granted to…
One key facet of the healthcare system is working to improve patient outcomes and finding new, effective, and innovative lines of treatment. According to Hematology Advisor, a study showed that…
On August 11, 2021, biopharmaceutical company Lantern Pharma, Inc. ("Lantern") shared the news that its small molecule drug candidate, LP-184 (hydroxyureamethylacylfulvene), received Orphan Drug designation from the FDA. This status…
Unfortunately, recurrent ovarian cancer can be difficult to treat and often comes with a poor prognosis. However, according to a news release from biopharmaceutical company IMV Inc. ("IMV"), the company…
Typically, statins, or HMG-CoA reductase inhibitors, are prescribed to help reduce cholesterol levels in the blood. But could this class of drugs be repurposed for the treatment of another group…
The FDA has recently granted ONCOFID®-P the Orphan Drug designation for the treatment of malignant mesothelioma (MM). This designation is reserved for therapies indicated for rare diseases, and it provides…
Orphan drug designation is granted in the United States to expedite the development and review of drugs and biologics intended to treat patients with rare conditions (over 200,000 Americans). Once…
HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma patients haven't seen a drug approval for their disease state in a decade. That is until the FDA approved Keytruda in combination with…
The FDA has recently granted Orphan Drug designation to TST1001, Transcenta Holding Limited's monoclonal antibody for gastric cancer/gastroesophageal junction (GC/GEJ). Prior research has demonstrated TST1001's anti-tumor activity, and ongoing research…
In the past, ibrutinib has been used to treat patients with a variety of conditions, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and chronic graft-versus-host disease (cGVHD). According…
Clinical guidelines are often used to improve patient treatment. These guidelines use evidence reviews, as well as an examination of other standards-of-care, to optimize patient care and outcomes. According…
If I told you that tiny bubbles could be used to more effectively treat cancer, would you believe me? Well, in the case of neuroblastoma, that might be correct. According…
On July 28, 2021, biopharmaceutical company Thetis Pharmaceuticals ("Thetis") shared that its small molecule Resolvin E1 (RvE1) therapy, TP-317, received Orphan Drug designation from the FDA. While TP-317 has…
According to a July 27 news release from biopharmaceutical company Day One Biopharmaceuticals ("Day One"), the company's therapeutic option DAY101 received Rare Pediatric Disease designation within the United States. Altogether,…
The FDA has recently approved KEYTRUDA (pembrolizumab) in combination with LENVIMA (lenvatinib) for the treatment of advanced endometrial carcinoma that is not mismatch repair deficiency or microsatellite instability-high. This approval…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
